Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Pivotal Factor Influencing Schizophrenia Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Schizophrenia Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the schizophrenia market size has seen robust growth. The projected growth from $5.82 billion in 2024 to $6.11 billion in 2025, signifies a compound annual growth rate (CAGR) of 5.0%. Factors such as increased demand for effective treatments, heightened awareness of mental health, governmental contributions, as well as expanding research and development efforts, can be credited for the growth witnessed in the historic period.

How Will the Schizophrenia Market Size Evolve and Grow by 2029?
Anticipated robust expansion is on the horizon for the schizophrenia market in the coming years, with projections estimating a rise to $7.54 billion by 2029, maintaining a compound annual growth rate (CAGR) of 5.4%. Factors contributing to this projected expansion in the specified timeframe include increasing utilization of personalized medicine, advancement in digital health solutions, improved antipsychotic drugs, and more widespread access to healthcare services. Looking ahead to the forecast period, the schizophrenia market is set to be shaped by the development of new drugs, a growing focus on early intervention and recovery-oriented care, coupled with an expanding pipeline of clinical trials for schizophrenia treatments.

View the full report here:
https://www.thebusinessresearchcompany.com/report/schizophrenia-global-market-report

What Drivers Are Propelling the Growth of Schizophrenia Market Forward?
The escalating influence of mental illnesses is predicted to intensify the expansion of the schizophrenia market. By definition, mental illnesses encompass a broad variety of psychological health disorders that significantly disrupt an individual's thoughts, emotions, moods, and behaviors, leading to difficulty in daily life functions and interpersonal relationships. The surging number of mental health disorders has ushered in a wave of progress in schizophrenia care and the creation of novel pharmaceutical compounds, thereby propelling the market's growth. For instance, the National Institute of Mental Health (NIMH), a division of the US Department of Health and Human Services, reported in March 2023 that an estimated 57.8 million people of 18 years and above were categorized under any mental illness (AMI), totaling to 22.8% of all adults in the United States. The prevalence of AMI was highest among young adults aged 18-25 years (33.7%), followed by people aged 26-49 years (28.1%) and those aged 50 and beyond (15.0%). Therefore, the rising prevalence of mental illnesses is a catalyst for the growth of the schizophrenia market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12869&type=smp

Which Emerging Trends Are Transforming the Schizophrenia Market in 2025?
Key players in the schizophrenia market are employing innovative technologies like automated psychological therapy to consolidate their market standing. This therapy uses technology, such as virtual reality (VR), to provide automated or self-guided psychological treatment. For example, OxfordVR Limited, a digital therapeutic company based in Switzerland, unveiled its gameChangeVR technology in April 2022. This technology provides a 6-week automated VR treatment that delivers cognitive behavioral therapy (CBT) in secure and immersive virtual environments. The VR-based automated psychological therapy caters to individuals with mental health issues, with a virtual coach guiding the users instead of a physical therapist, thus broadening the scope of patient treatment. This marks the first instance of digital therapy of any nature being proven to assist with the treatment of schizophrenia and mood disorders with psychotic symptoms.

What Are the Key Segments in the Schizophrenia Market?
The schizophrenia market covered in this report is segmented -

1) By Type: Catatonic Schizophrenia, Paranoid Schizophrenia, Undifferentiated Schizophrenia, Hebephrenic Schizophrenia, Residual Schizophrenia, Other Types
2) By Treatment: First-Generation Antipsychotics, Second-Generation Antipsychotics, Third-Generation Antipsychotics, Psychotherapies, Other Treatments
3) By Route of Administration: Oral, Injectables

Subsegments:
1) By Catatonic Schizophrenia: Waxy Flexibility, Stupor, Agitation, Catatonic Excitement
2) By Paranoid Schizophrenia: Delusions Of Persecution, Auditory Hallucinations, Paranoid Ideation
3) By Undifferentiated Schizophrenia: Symptoms Not Specific To Other Types, Mixed Symptoms Of Schizophrenia
4) By Hebephrenic Schizophrenia (Disorganized Schizophrenia): Disorganized Behavior, Disorganized Speech, Emotional Flatness
5) By Residual Schizophrenia: History Of Schizophrenia With Low-Level Symptoms, Social Withdrawal, Mild Hallucinations Or Delusions
6) By Other Types: Schizoaffective Disorder, Brief Psychotic Disorder, Delusional Disorder

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12869&type=smp

Who Are the Key Players Shaping the Schizophrenia Market's Competitive Landscape?
Major companies operating in the schizophrenia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Otsuka Holdings Co. Ltd., Biogen Inc., Daiichi Sankyo Co. Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Recordati SpA, Lundbeck A/S, Neurocrine Biosciences Inc., Torrent Pharmaceutical Ltd., Alkermes PLC, Indivior PLC, Vanda Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., PsychoGenics Inc., Karuna Therapeutics Inc., Minerva Neurosciences Inc.

What Geographic Markets Are Powering Growth in the Schizophrenia Market?
North America was the largest region in the schizophrenia market in 2024. The regions covered in the schizophrenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12869

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.